Accelerator Mass Spectrometry In Radiolabelled Analysis

Poster detailing the evolution of accelerator mass spectrometry for radiolabeled sample analysis in clinical research, with images and data charts.

Poster Authors:

Pharmaron UK Ltd, Hertford Road Hoddesdon Hertfordshire, EN11 9FH, UK

Revolutionizing Phase 1 Clinical Studies with AMS

Accelerator mass spectrometry (AMS) is now a cornerstone technology in early-phase clinical research, enabling the detection of trace levels of radiolabelled analytes like ¹⁴C in biological matrices. Once exclusive to radiocarbon dating, AMS is now integral to sample analysis for human ADME and bioavailability studies, offering unmatched sensitivity and operational efficiency.

What Is Accelerator Mass Spectrometry (AMS)?

AMS is a highly sensitive technique capable of quantifying ¹⁴C-labeled compounds at attomole levels in biological samples. It allows researchers to:

Detect minute radiolabelled drug concentrations
Trace metabolic pathways with extreme precision
Support microtracer studies with very low radiation doses

Its application has expanded across exploratory microdosing (Phase 0) and standard Phase 1 clinical trials for full ADME and IVPK profiling.

Capabilities

Knowledge Center

AMS and Carbon-14 Radiolabelled Biologics

Bioanalysis Services

Accelerator Mass Spectrometry (AMS)

Connect with a Scientific Expert

Name(Required)

First Last

Company Name(Required)

Job Title(Required)

Country(Required)

State(Required)

Message

Email(Required)

This field is hidden when viewing the form

Lead Source(Required)

By completing and submitting this form, you acknowledge that you have read and understood our Privacy Policy, and you consent to the collection and processing of your personal data by Pharmaron for the purpose of responding to your inquiry. You also agree to be contacted by Pharmaron regarding relevant services and updates. You may withdraw your consent at any time.

Why Use AMS for Radiolabelled Analysis?

AMS-Enabled Study Types

Microtracer ADME: Measures mass balance, recovery, and metabolite profiles
Microtracer IVPK: Determines absolute bioavailability (F) in a single-cohort setup
Parent drug quantification: Supports low-dose, high-accuracy assessments

AMS streamlines study designs by combining radiolabel and therapeutic doses in a single cohort, reducing timelines and subject exposure compared to traditional two-arm crossover trials.

Technological Evolution in AMS Systems

The evolution from bulky pelletron accelerators to Ionplus low-energy AMS systems has transformed clinical applications:

Compact footprint: From 250 m² (5MV tandem) to 12 m² (Ionplus LEA)
Faster sample processing and real-time interfacing
Regulatory-compliant software and user-friendly operation

These upgrades have increased AMS accessibility, allowing its integration into standard clinical sample analysis workflows.

Pharmaron’s AMS Capabilities

350+ compounds analyzed using AMS
160 Phase 1 trials supported since 2018
4 AMS systems across three global labs
70 drugs supported in FDA approvals

Pharmaron delivers rapid, validated AMS data tailored to regulatory expectations, supporting a wide range of compound types across various therapeutic areas.

References:

Discover how microtracer AMS can fast-track your clinical studies.

Learn more by reading our poster to learn how modern accelerator mass spectrometry can transform your radiolabelled clinical strategy. Reduce radiation, enhance sensitivity, and streamline data collection with confidence.